Literature DB >> 7447963

Impaired response to pneumococcal vaccine in systemic lupus erythematosus.

M P Jarrett, G Schiffman, P Barland, A I Grayzel.   

Abstract

An immunization program with pneumococcal vaccine was carried out in 38 patients with systemic lupus erythematosus (SLE). Mean antibody levels at 1 month and 1 year were significantly lower than in normal controls. This decreased response did not correlate with drug therapy at the time of immunization. Other parameters such as anergy state, renal function, and serum immunoglobulin levels also did not correlate with antibody response. There were no adverse effects noted in the vaccinated group in comparison to matched non-vaccinated SLE patients.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7447963     DOI： 10.1002/art.1780231110

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


  10 in total

Review 1.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

2.  Heptavax-B in pediatric dialysis patients: effect of systemic lupus erythematosus. Chesapeake Pediatric Nephrology Study Group.

Authors:  M M Moxey-Mims; K Preston; B Fivush; F McCurdy
Journal:  Pediatr Nephrol       Date:  1990-03       Impact factor: 3.714

3.  Immunogenicity of pneumococcal vaccines in comorbid autoimmune and chronic respiratory diseases.

Authors:  Koji Kuronuma; Hiroki Takahashi
Journal:  Hum Vaccin Immunother       Date:  2019-01-30       Impact factor: 3.452

Review 4.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

5.  Immune response to influenza vaccine in children with inflammatory bowel disease.

Authors:  Ying Lu; Denise L Jacobson; Lori A Ashworth; Richard J Grand; Anthony L Meyer; Monica M McNeal; Matt C Gregas; Sandra K Burchett; Athos Bousvaros
Journal:  Am J Gastroenterol       Date:  2009-01-27       Impact factor: 10.864

Review 6.  Vaccination of patients with autoimmune inflammatory rheumatic diseases.

Authors:  Johanna Westra; Christien Rondaan; Sander van Assen; Marc Bijl
Journal:  Nat Rev Rheumatol       Date:  2014-12-09       Impact factor: 20.543

7.  B cell activity in systemic lupus erythematosus: depressed in vivo humoral immune response to a primary antigen (haemocyanin) and increased in vitro spontaneous immunoglobulin synthesis.

Authors:  C G Kallenberg; P C Limburg; C Van Slochteren; F J Van der Woude; T H The
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

Review 8.  Asplenism and systemic lupus erythematosus.

Authors:  F Lioté; J Angle; N Gilmore; C K Osterland
Journal:  Clin Rheumatol       Date:  1995-03       Impact factor: 2.980

Review 9.  Recommendations and barriers to vaccination in systemic lupus erythematosus.

Authors:  Megha Garg; Naaima Mufti; Tara N Palmore; Sarfaraz A Hasni
Journal:  Autoimmun Rev       Date:  2018-08-11       Impact factor: 9.754

10.  Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations.

Authors:  Christien Rondaan; Victoria Furer; Marloes W Heijstek; Nancy Agmon-Levin; Marc Bijl; Ferdinand C Breedveld; Raffaele D'Amelio; Maxime Dougados; Meliha C Kapetanovic; Jacob M van Laar; Annette Ladefoged de Thurah; Robert Landewé; Anna Molto; Ulf Müller-Ladner; Karen Schreiber; Leo Smolar; Jim Walker; Klaus Warnatz; Nico M Wulffraat; Sander van Assen; Ori Elkayam
Journal:  RMD Open       Date:  2019-09-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.